{
  "trial_id": "NCT02597127",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, history of ASCVD, history of diabetes, history of familial hypercholesterolemia, baseline LDL-C levels, fasting triglyceride levels, calculated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering therapies, systolic blood pressure, diastolic blood pressure, glycated hemoglobin A1c (HbA1c), alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, total bilirubin levels, history of heart failure, history of cardiac arrhythmia, history of hemorrhagic stroke, history of major adverse cardiac events, history of hypertension, history of liver disease, history of alcohol or drug abuse, pregnancy status, use of contraception, life expectancy, cognitive impairment status, previous treatment with monoclonal antibodies directed at PCSK9.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "history of ASCVD",
        "history of diabetes",
        "history of familial hypercholesterolemia",
        "baseline LDL-C levels",
        "fasting triglyceride levels",
        "calculated glomerular filtration rate (eGFR)",
        "use of statins",
        "use of other lipid-lowering therapies",
        "systolic blood pressure",
        "diastolic blood pressure",
        "glycated hemoglobin A1c (HbA1c)",
        "alanine aminotransferase (ALT) levels",
        "aspartate aminotransferase (AST) levels",
        "total bilirubin levels",
        "history of heart failure",
        "history of cardiac arrhythmia",
        "history of hemorrhagic stroke",
        "history of major adverse cardiac events",
        "history of hypertension",
        "history of liver disease",
        "history of alcohol or drug abuse",
        "pregnancy status",
        "use of contraception",
        "life expectancy",
        "cognitive impairment status",
        "previous treatment with monoclonal antibodies directed at PCSK9."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, History of ASCVD, History of ASCVD-risk equivalents, Baseline LDL-C, Baseline triglycerides, Baseline eGFR, Baseline HbA1c, Use of statins, Use of lipid-lowering therapies, Systolic Blood Pressure, Diastolic Blood Pressure,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "History of ASCVD",
        "History of ASCVD-risk equivalents",
        "Baseline LDL-C",
        "Baseline triglycerides",
        "Baseline eGFR",
        "Baseline HbA1c",
        "Use of statins",
        "Use of lipid-lowering therapies",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, History of Atherosclerotic Cardiovascular Disease, Diabetes, Familial Hypercholesterolemia, LDL-C, Triglycerides, eGFR, Statin Use, Ezetimibe Use, NYHA Class, Left Ventricular Ejection Fraction, Systolic Blood Pressure, Diastolic Blood Pressure, HbA1c.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "History of Atherosclerotic Cardiovascular Disease",
        "Diabetes",
        "Familial Hypercholesterolemia",
        "LDL-C",
        "Triglycerides",
        "eGFR",
        "Statin Use",
        "Ezetimibe Use",
        "NYHA Class",
        "Left Ventricular Ejection Fraction",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "HbA1c"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), history of ASCVD or ASCVD-risk equivalents, type of ASCVD or ASCVD-risk equivalents, Framingham Risk Score, LDL-C at screening, triglyceride level at screening, glomerular filtration rate, statin use, lipid-lowering therapy use, New York Heart Association (NYHA) class, left ventricular ejection fraction, history of cardiac arrhythmia, history of hemorrhagic stroke, history of major adverse cardiac event, systolic and diastolic blood pressure, glycated hemoglobin A1c (HbA1c), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, total bilirubin level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "history of ASCVD or ASCVD-risk equivalents",
        "type of ASCVD or ASCVD-risk equivalents",
        "Framingham Risk Score",
        "LDL-C at screening",
        "triglyceride level at screening",
        "glomerular filtration rate",
        "statin use",
        "lipid-lowering therapy use",
        "New York Heart Association (NYHA) class",
        "left ventricular ejection fraction",
        "history of cardiac arrhythmia",
        "history of hemorrhagic stroke",
        "history of major adverse cardiac event",
        "systolic and diastolic blood pressure",
        "glycated hemoglobin A1c (HbA1c)",
        "alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels",
        "total bilirubin level"
      ]
    }
  }
}